Australia’s TGA Announces End of EpiPen Shortage

Australia’s Therapeutic Goods Administration declared that a shortage of EpiPen 300 mcg adrenaline auto-injectors has been resolved.

Alphapharm, doing business as Mylan Australia, confirmed that patient needs are currently being met now that there is a sufficient supply of the auto-injectors.

The supply shortage, caused by manufacturing delays at a Pfizer facility which produces the auto-injectors for Mylan, began in April 2018.